Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) and emphasizing the importance of translating clinical trial evidence and guideline recommendations into individualized patient care.
Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk criteria in guiding treatment decisions for advanced renal cell carcinoma (RCC) and explains why its influence has evolved in the current therapeutic landscape.
Dr. Monty Pal reviews how current clinical guidelines support both immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combinations and dual immunotherapy (IO/IO) as frontline treatment options for advanced renal cell carcinoma (RCC).
Dr. Monty Pal compares the available immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combination regimens for the first-line treatment of advanced renal cell carcinoma (RCC) and explains the clinical rationale behind his preferred treatment approach.
Dr. Monty Pal discusses how the increasing use of adjuvant immunotherapy has introduced new considerations for the management of advanced renal cell carcinoma (RCC).
Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting how he incorporates disease risk, clinical presentation, and treatment goals into routine decision making.
Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the importance of optimizing first-line therapy, noting that many patients may not receive multiple subsequent lines of treatment.
Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the type of first-line immunotherapy regimen previously received.
Dr. Monty Pal discusses how patient- and disease-specific characteristics influence treatment sequencing decisions for advanced renal cell carcinoma (RCC) beyond the first-line setting.
Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC).
Dr. Monty Pal reviews emerging clinical evidence evaluating belzutifan-based treatment strategies in advanced renal cell carcinoma (RCC), with particular focus on the LITESPARK-011 trial comparing lenvatinib plus belzutifan with cabozantinib.
Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he applies current guideline recommendations alongside individualized clinical decision making in routine practice.
Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.